Применение ацетилсалициловой кислотыдля профилактики инсульта

1. Соllaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
2. Patrono C, Coller B, Dalen J et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001; 119: 39S–63S.
3. Taylor D, Barnett H, Haynes R et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. Lancet 1999; 353: 2179–84.
4. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261–6.
5. Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease 1988; 35: 154–76.
6. Cairns JA, Gent M, Singer J et al. Aspirin, sulfinpyrasone, or both in unstable angina. Results of Canadian multicenter trial. N Engl J Med 1985; 313: 1369–75.
7. Lewis H, Davis J, Arhibald D et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396–403.
8. Antiplatelet Trialist' Collaboration. Collaborative overview of randomized trials of anplatelet therapy-1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81–106.
9. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISK Group. Lancet 1990; 336: 827–30.
10. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendation of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406–32.
11. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaboration group. Lancet 1988; 8: 349–60.
12. Ridker PM, Manson JE, Gaziano JM et al. Low-dose aspirin therapy for chronic stabile angina: a randomized, placebo controlled clinical trial. ANN. Intern Med 1991; 114: 835–9.
13. Juul-Moller S, Edvardsson N, Jahnmatz B et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421–5.
14. Antiplatelet Trialist' Collaborative overview of randomized trials of anplatelet therapy-II: maintenance of vascular graft or arterial potency by antiplatelet therapy. Br Med J 1994; 308: 159–68.
15. Warlow C. Secondary prevention of stroke. Lancet 1992; 339: 724–7.
16. McConnel H. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71–86.
17. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertention; principal results of Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1988; 351: 1766–72.
18. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 161–72.
19. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med 2002; 136: 157–60.
20. Gum PA, Tramilarasan M, Watanabe J et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. JAMA 2001; 286 (10): 1187–94.
21. Ridker PM, Manson JE, Buring JE et al. The effect of chronic platelet inhibition with low-doses aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am Heart J 1991; 122 (6): 1588–92.
22. Medical Reseach Council. Randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk: the Medical Research Council's General Practice Research Framework Thrombosis Prevention Trial. Lancet 1998; 351: 233–41.
23. Manson JE, Stampfer MJ, Colditz GA et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991; 266 (4): 521–27.
24. Sanmuganathan PS, Ghahramani P Jackson PR et al. Aspirin for the primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001; 85 (3): 265–71.
25. Caims J, Theroux P, Lewis D et al. Antithrombotic Agents in Coronary Artery Disease. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001; 119: 228S–252S.
26. Collins R, Baigent C, Sandercock P, Peto R. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomized trials. Antiplatelet Trialists' Collaboration. BMJ 1994; 309 (6963): 1215–7.
27. Bousser MG. Antithrombotic strategy in stroke. Thromb Haemost 2001; 86: 1–7.
28. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. The SALT Collaborative Group. Lancet 1991; 338 (8779): 1345–9.
29. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from he general practice research database. Heart 2001; 86 (3): 284–8.
30. Colwell JA. Treatment for the procoagulant state in type 2 diabetes. Endocrinol. Metab. Clin North Am 2001; 30 (4): 1011–30.
31. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertention Optimal Treatment (HOT) study. J Hypertens 1999; 17: 1041–5.
32. Vane JR, Meade TW. Second European Stroke prevention Study (ESPS2): clinical and pharmacological implications. J Neurol Sci 1997; 145 (2): 123–5.
33. Diener HC, Cunha L, Forbes C et al. European stroke prevention Study 2: dipyridamol and acetylsalicylic acid in the secondary revention of stroke. J Neurol Sci 1996; 143: 1–13.
34. Scrutinio D, Cimminiello C, Marubini E et al. Tialopidine versus aspirin after myocardial infarction (STAMI) trial. Am Coll Cardiol 2001; 37 (5): 1259–65.
35. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischeamic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 9038, 1329–39.
36. Easton JD. Future perspectives for optimizing oral antiplatelet therapy. Cerebrovasc Dis 2001; 11: S223–8.
37. Dammann HG, Burhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol. Ther. 1999; 13 (8): 1109–14.
38. Cole AT, Hudson N, Liew LC. et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Aliment Pharmacol Ther 1999; 13 (2): 187–93.
39. Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344 (13): 967–73.
40. Kelly JP, Kaufman DW, Jugelon JM et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413–16.
41. Petroski D. Gastric safety and enteric-coated aspirin. Lancet 1997; 349.
42. Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 1993; 15: 314–20.
43. Petroski D. Endoscopic comparison of various preparations: gastric mucosal adaptability to aspirin restudied. Curr Ther Res 1989; 45: 345–54.
44. Savon J, Allen ML, DiMarino AJ. Gastrointestinal blood loss with low-dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastrointerol 1995; 90: 581–85.
45. Latini R, Santoro E, Masson S et al. Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial. Heart Dis 2000; 2 (3): 185–90.
46. Cleland JG, John J, Houghton T. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart hailure? Curr Opin Nephrol Hypertens 2001; 10 (5): 625–31.
47. Mahe I, Meune C, Diemer M et al. Interaction between aspirin and ACE inhibitors in patients with heart failure. Drug Saf 2001; 24 (3): 167–82.
48. Latini R, Tognoni G, Maggioni A et al. Clinical effect of early ACE inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: meta-analysis of individual data from nearly 96000 randomized patients. J Am Coll Cardiol 2000; 35: 1801–7.

О.Д.Остроумова